Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 4,782 matching trials from the live ClinicalTrials.gov search.
Conditions
Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Basal Cell Carcinomas
Interventions
PulseCure pulse generator and Derm-pulse electrode
Device
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oakland, California
Conditions
Myeloma, Multiple
Interventions
Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more
Conditions
Multiple Myeloma
Interventions
Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Eatwell Clinical Trial (R01)

NCT07225881
Conditions
Cancer Prevention, Dietary Guidelines
Interventions
Eatwell, Nutrition Education Control Group
Behavioral · Other
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
CPG 7909, Chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
17
States / cities
Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more
Conditions
Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy
Interventions
leteprinim potassium (Neotrofin)
Drug
Lead sponsor
NeoTherapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Berkeley, California • Burbank, California • Mission Hills, California + 3 more
Conditions
Non-small Cell Lung Cancer
Interventions
Pralatrexate, Erlotinib, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more
Completed Not applicable Interventional Results available

HALO Patient Registry: Ablation of Barrett's Esophagus

NCT00848237
Conditions
Barrett Esophagus
Interventions
Radiofrequency Ablation (HALO Ablation Systems)
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
Not listed
Enrollment
5,521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Knoxville and Other US Cities, California
Conditions
Prostatic Neoplasms
Interventions
MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cleveland, Ohio
Conditions
Solid Tumor
Interventions
ONO-7579
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lake Success, New York • New York, New York • Greenville, South Carolina + 1 more
Conditions
Multiple Myeloma
Interventions
bortezomib, thalidomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, CAR-T
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Co-ArgI-PEG modified human arginase I
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Conditions
Multiple Myeloma
Interventions
Ide-cel (bb2121)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Venetoclax, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more
Enrolling by invitation Phase 1 Interventional

Clinical Trial to Treat Stage IV Cancer Patients

NCT06674538
Conditions
Soft Tissue Cancer
Interventions
Moonshot antibodies
Drug
Lead sponsor
Moonshot Antibodies
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Hershey, Pennsylvania
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

NCT03863184
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Lenalidomide, Rituximab, Obinutuzumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Multiple Myeloma
Interventions
high dose chemotherapy then autologous hematopoietic cell transplant
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Myeloma
Interventions
Hyperbaric oxygen
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, New York
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas